Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Database
Language
Publication year range
1.
Lett Appl Microbiol ; 71(5): 550-556, 2020 Nov.
Article in English | MEDLINE | ID: mdl-32780870

ABSTRACT

A series of experiments was conducted to identify the molecular species responsible for surface active emulsification (surfactant) bioactivity in Bacillus subtilis subsp. subtilis strain ATCC PTA-125135, and to describe culture conditions to support the enriched production of said bioactivity in cultured plaque of the strain. The assay for methylene blue active substances (MBAS) was found to be suitable for describing surfactant activity, where a solvent-extracted molecular fraction from the biofilm was found to retain surfactant activity and positively quantified as MBAS. Furthermore, an HPLC-refined protein fraction was found to quantify as MBAS with approximately 1·36-fold or greater surfactant activity per mol than sodium dodecyl sulphate, and a proteomic analysis of solvent extracted residues confirmed that biofilm surface layer protein BslA was a primary constituent of extracted residues. Surfactant bioactivity, quantified as MBAS, was enriched in cultured plaque by the supplementation of culture media with calcium chloride or calcium nitrate.


Subject(s)
Bacillus/metabolism , Biofilms , Calcium/metabolism , Methylene Blue/metabolism , Surface-Active Agents/metabolism , Culture Media/metabolism , Proteomics , Sodium Dodecyl Sulfate/metabolism
2.
Poult Sci ; 96(8): 2595-2600, 2017 Aug 01.
Article in English | MEDLINE | ID: mdl-28431095

ABSTRACT

Avi-Lution® is a defined, patented, synbiotic product containing Saccharomyces cerevisiae, Enterococcus faecium, and Bacillus spp. Broiler chickens (n = 1,250) were experimentally treated as uninoculated controls (uCon), inoculated controls (iCon) with Clostridium perfringens, or inoculated and treated with bacitracin methylene disalicylate (BMD) at 55 mg/kg as an infected/treated control or Avi-Lution® at 1.0 (AvL1) or 2.0 (AvL2) g/kg in feed for 42 d. Each treatment was applied to 10 replicate pens of 25 straight-run, newly hatched chicks. Pens treated with AvL1, AvL2, or BMD showed improved growth, feed efficiency, or mortality from necrotic enteritis compared with iCon pens at d 14, 28, and 42. No differences in these measurements, however, were observed between pens treated with AvL1 and AvL2, which suggests that Avi-Lution® was effective at 1.0 g/kg in feed. Despite improved performance, BMD, AvL1, and AvL2 treatments did not decrease the severity of intestinal lesion scores through 42 d of age compared with the infected control. These results demonstrate that Avi-Lution® improved growth performance and feed conversion rates in broilers challenged with Clostridium perfringens despite no difference in severity of intestinal lesion scores.


Subject(s)
Bacitracin/administration & dosage , Chickens , Clostridium Infections/veterinary , Clostridium perfringens/physiology , Poultry Diseases/prevention & control , Salicylates/administration & dosage , Synbiotics/administration & dosage , Animal Feed/analysis , Animals , Bacillus/chemistry , Bacitracin/pharmacology , Chickens/growth & development , Clostridium Infections/prevention & control , Clostridium perfringens/drug effects , Diet/veterinary , Dose-Response Relationship, Drug , Drug Resistance, Bacterial , Enterococcus faecium/chemistry , Male , Random Allocation , Saccharomyces cerevisiae/chemistry
SELECTION OF CITATIONS
SEARCH DETAIL
...